managing adverse events associated with tkis in cml
Published 2 years ago • 116 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
4:22
management of btk class driven adverse events
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
0:58
management strategies for acute and chronic gvhd following allosct
-
2:46
optimizing preceding and consolidation therapies to prevent post-car-t relapse in b-all
-
1:00:23
implementing remote clinical trial monitoring to ensure continuity of trials and data preservation
-
26:54
episode 5: how will rtsm impact clinical data?
-
6:41
plan or act? the journey, episode 3, season 2
-
1:31
tocilizumab for car-t adverse event management
-
0:53
follow-up from a phase i study of cart-ddbcma for the treatment of r/r multiple myeloma
-
2:47
management of relapse following allohsct in patients with aml and mds
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
2:38
emerging strategies for the management of relapsed aml
-
1:05
the importance of using mrd to guide treatment decisions in all
-
21:53
management of adverse events with newer therapeutic approaches
-
1:09
strategies to overcome azacitidine resistance in mds: combination strategies & mutation analysis
-
1:41
the importance of integrating genomic and cytogenetic data in treatment decisions for aml
-
1:52
what is my critical event
-
1:31
ongoing trials in aml and hr-mds: enhance, enhance-2 and enhance-3
-
0:47
overview of the phase iii enhance trial schema
-
2:26
feasibility of sequential treatment with cd19-targeted agents in patients with lbcl
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma